Misted chemotherapy shows promise for advanced stomach cancer in early trial

NCT ID NCT06675136

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new method of delivering chemotherapy directly into the abdomen as a fine mist under pressure (PIPAC) for people with stomach cancer that has spread to the lining of the belly. The study combines this misted chemotherapy (nab-paclitaxel) with standard second-line drugs given through a vein. The main goals are to find the safest dose and see if the combination is tolerable. About 30 participants who have already tried one line of treatment will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nab-paclitaxel (a form of chemotherapy) given as a pressurized mist into the abdomen, plus paclitaxel and ramucirumab (another chemotherapy and an antibody) given through a vein
What this could lead to
If this works, it could offer a new treatment option for stomach cancer that has spread to the lining of the belly, potentially slowing the disease.
What could go wrong
This is a very early (Phase 1) trial with only 30 people, so the main goal is safety, not effectiveness. The combination may cause serious side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IVB GASTRIC CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.